avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2016-6-1-63-69avk-493Research ArticleРАЗБОР КЛИНИЧЕСКИХ СЛУЧАЕВANALYSIS OF CLINICAL CASESГЕПАТОЦЕЛЛЮЛЯРНЫЙ РАК. СОВРЕМЕННЫЕ ДОСТИЖЕНИЯ В ДИАГНОСТИКЕ И ЛЕЧЕНИИHEPATOCELLULAR CARCINOMA. RECENT ADVANCES IN DIAGNOSIS AND TREATMENTЧернобровкинаТ. Я.ChernobrovkinaT. Y.tanyura541@mail.ruЯнковскаяЯ. Д.YankovwskayaY. D.ГБОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», кафедра инфекционных болезней и эпидемиологии лечебного факультета, г. Москва, РоссияРоссияPirogov Russian National Research Medical University, Department of Infectious Diseases and Epidemiology, medical faculty, Moscow, RussiaRussian Federation201609032016616369Copyright © Чернобровкина Т.Я., Янковская Я.Д., 20162016Чернобровкина Т.Я., Янковская Я.Д.Chernobrovkina T.Y., Yankovwskaya Y.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/493

В аналитическом обзоре описаны механизмы гепатоканцерогенеза. Представлена классификация гепатоцеллюлярной карциномы (ГЦК), этиология, диагностическая тактика при подозрении на ГЦК и варианты лечения. Основными факторами риска развития ГЦК при HBVинфекции считают — цирроз печени (ЦП), мужской пол, возраст старше 50 лет, уровень HBV DNA > 104 копий/мл, положительный HBeAg в сыворотке крови, генотип С HBV, мутации в области core promoter, повышеннyю активность АЛТ в крови. В обзоре представлен клинический случай ГЦК у больной с хроническим гепатитом С и исходом в цирроз печени.

In analytical review describes the pathogenic mechanisms of hepatocarcinogenesis and some risk factors of grow more serious progress of HCC. There modern classifications of HCC, aetiology, some of diagnostic methods in suspicion on HCC and different variants of treatment by means of medical drugs and nonmedical tactics are presented. The main risk factors for the development HCC — liver cirrhosis, man, the age of 50 year, HBV DNA > 104 copies/ml, positive HBeAg in blood serum, genotype С HBV, mutations in the area core promoter, increased activity ALT. The clinical example of patient with HCC and the outcome of liver cirrhosis are illustrated. 

Гепатоцеллюлярная карциномаскринингHBV-инфекцияHCV-инфекциягепатоканцерогенезальфафетопротеинлечение ГЦКHepatocellular carcinomascreeningHBV-infectionHCV- infectionhepatocarcinogensalfafetoproteintreatment HCCReferencesГеттуева А.А., Сторожаков Г.И., Лепков С.В., Эттингер О.А., Косюра С.Д. Влияние вирусного гепатита В и С на течение и прогноз гепатоцеллюлярной карциномы. Лечебное дело. 2012; 2: 15-19.Gatcheva A.A., Storozhakov G.I., Lepkov S.V., Ettinger, A.O., Kosura S.D. The Influence of viral hepatitis B and C on the course and prognosis of hepatocellular carcinoma. Medical care. 2012; 2: 15-19.Маев И.В., Дичева Д.Т., Жиляев Е.В. и др. Трудности диагностики гепатоцеллюлярной карциномы. Consilium Med. 2010; 8: 63-66.Maev I.V., Dicheva D.T., Zhilyaev E.V., etc. Difficulties in the diagnosis of hepatocellular carcinoma. Consilium Med. 2010; 8: 63 -66.Хазанов А.И. Гепатоцеллюлярная карцинома. В кн.: Гастроэнтерология и гепатология. М., 2011; 759-766.Khazanov A.I. Hepatocellular carcinoma. In the book: Gastroenterology and Hepatology. M., 2011; 759-766.Abelev G.I. Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data. Cancer Res. 1968; 28(7): 1344–1350.Abelev G.I. Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data. Cancer Res. 1968; 28(7): 1344–1350.Beasley R., Hwang L., Lin C. et al. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet. 1981; 221: 1129–1133.Beasley R., Hwang L., Lin C. et al. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet. 1981; 221: 1129–1133.Beasley R. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988; 61: 1942–1956.Beasley R. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988; 61: 1942–1956.Bralet M.P. et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology. 2000; 32: 200-204.Bralet M.P. et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology. 2000; 32: 200-204.Bergstrand C.G., Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand. J. Clin. Lab. Invest. 1956; 8(2): 174.Bergstrand C.G., Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand. J. Clin. Lab. Invest. 1956; 8(2): 174.Degos F., Christidis C., Ganne-Carrie N. et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000; 47: 131–136.Degos F., Christidis C., Ganne-Carrie N. et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000; 47: 131–136.Debruyne E.N., Delanghe J.R. Diagnosing and monitoring hepatocellular carcinoma with alpha fetoprotein: new aspects and applications. Clin. Chim. Acta. 2008; 395(1–2): 19–26.Debruyne E.N., Delanghe J.R. Diagnosing and monitoring hepatocellular carcinoma with alpha fetoprotein: new aspects and applications. Clin. Chim. Acta. 2008; 395(1–2): 19–26.Fattovich G. et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am. J. Gastroenterol. 2002; 97: 2886-2895.Fattovich G. et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am. J. Gastroenterol. 2002; 97:2886-2895.Farci P., Niro G. Clinical Features of Hepatitis D. Semin. Liver. Dis. 2012; 32: 228–236.Farci P., Niro G. Clinical Features of Hepatitis D. Semin. Liver. Dis. 2012; 32: 228–236.Fattovich G., Giustina V., Christensen E. et al. Influence of hepatitis Delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut. 2000; 46: 420–426.Fattovich G., Giustina V., Christensen E. et al. Influence of hepatitis Delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut. 2000; 46: 420–426.Gorog D., Regoly-Merei J., Paku S. et al. Alphafetoprotein expression is a potential prognostic marker in hepatocellular carcinoma. World J. Gastroenterol. 2005; 11: 5015–5018.Gorog D., Regoly-Merei J., Paku S. et al. Alphafetoprotein expression is a potential prognostic marker in hepatocellular carcinoma. World J. Gastroenterol. 2005; 11: 5015–5018.Kew M.C. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update. J. Viral. Hepat. 2012; 20: 345–349.Kew M.C. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update. J. Viral. Hepat. 2012; 20: 345–349.Liebman H.A. et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N. Engl. J. Med. 1984; 310: 1427-1431.Liebman H.A. et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N. Engl. J. Med. 1984; 310: 1427-1431.Lopez J.B. Recent developments in the first detection of hepatocellular carcinoma. Clin. Biochem. Rev. 2005; 26: 65-79.Lopez J.B. Recent developments in the first detection of hepatocellular carcinoma. Clin. Biochem. Rev. 2005; 26: 65-79.Montalto G., Cervello M., Giannitrapani L. et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann. N. Y. Acad. Sci. 2002; 963: 13–20.Montalto G., Cervello M., Giannitrapani L. et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann. N. Y. Acad. Sci. 2002; 963: 13–20.Malaguarnera G. et al. Serum markers of hepatocellular carcinoma. Dig. Dis. Sci. 2010; 55: 2744-2755.Malaguarnera G. et al. Serum markers of hepatocellular carcinoma. Dig. Dis. Sci. 2010; 55: 2744-2755.Marrero J.A. et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003; 37: 1114-1121.Marrero J.A. et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003; 37: 1114-1121.McMahon B.J. et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000; 32: 842-846.McMahon B.J. et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000; 32: 842-846.Negro F., Papotti M., Taraglio S. et al. Relationship between hepatocyte proliferation and hepatitis delta virus replication in neoplastic and non-neoplastic liver tissues. J. Viral. Hepat. 1997; 4: 93–98.Negro F., Papotti M., Taraglio S. et al. Relationship between hepatocyte proliferation and hepatitis delta virus replication in neoplastic and non-neoplastic liver tissues. J. Viral. Hepat. 1997; 4: 93–98.Nakagawa T. et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int. J. Oncol. 1999; 14: 281-286.Nakagawa T. et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int. J. Oncol. 1999; 14: 281-286.Okuda H., Obata H., Motoike Y., Hisamitsu T. Clinicopathological features of hepatocellular carcinoma-comparison of hepatitis B seropositive and seronegative patients. Hepatogastroenterology. 1984; 31: 64-68.Okuda H., Obata H., Motoike Y., Hisamitsu T. Clinicopathological features of hepatocellular carcinoma-comparison of hepatitis B seropositive and seronegative patients. Hepatogastroenterology. 1984; 31: 64-68.Sangiovanni A., Prati G., Fasani P. et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006; 43: 1303–1310.Sangiovanni A., Prati G., Fasani P. et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17‑year cohort study of 214 patients. Hepatology. 2006; 43: 1303–1310.Shiratori Y. et al. Characteristic difference of hepatocellular carcinoma between hepatitis Band Cviral infection in Japan. Hepatology. 1995; 22: 1027-1033.Shiratori Y. et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology. 1995; 22: 1027-1033.Van Nieuwkerk C.M., Rauws E.A., Tytgat G.N., et al. Diagnosis and treatment of hepatocellular carcinoma: new approaches. New Tijdschr Geneeskd. 1996; 140(17): 922-926.Van Nieuwkerk C.M., Rauws E.A., Tytgat G.N., et al. Diagnosis and treatment of hepatocellular carcinoma: new approaches. New Tijdschr Geneeskd. 1996; 140(17): 922-926.Yano M., Kumada H., Kage M. et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996; 23: 1334–1340.Yano M., Kumada H., Kage M. et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996; 23: 1334–1340.Yoshima H. et al. Structure of the asparagine-linked sugar chains of alpha-fetoprotein purified from human ascites fluid. Cancer Res. 1980; 40(11): 4276–4281.Yoshima H. et al. Structure of the asparagine-linked sugar chains of alpha-fetoprotein purified from human ascites fluid. Cancer Res. 1980; 40(11): 4276–4281.Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004; 130: 417-422.Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004; 130: 417-422.

The authors declare that there are no conflicts of interest present.